IMPROVED SEXUAL FUNCTION DURING RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY

被引：47

作者：

BOMMER, J ^{[1
]}

KUGEL, M ^{[1
]}

SCHWOBEL, B ^{[1
]}

RITZ, E ^{[1
]}

BARTH, HP ^{[1
]}

SEELIG, R ^{[1
]}

机构：

[1] INST IMMUNOL, KARLSRUHE, GERMANY

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 1990年 / 5卷 / 03期

关键词：

Dialysis; Erythropoietin; Hormones; Sexual function; Sexual hormones;

D O I：

10.1093/ndt/5.3.204

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

In seven male haemodialysis patients, living with a constant sexual partner, sexual life (self-administered questionnaire) and sex hormones were evaluated before and 3 or 10 months after commencement of recombinant human erythropoietin (rHuEpo) therapy respectively. Haematocrit increased from 22.2 ± 2.1% to 30.6 ± 1% with a maintenance dose of 140 ± 55 U/kg per week. Two patients were hypertensive before and after rHuEpo therapy; antihypertensive medication was kept constant during the study. Self-reported sexual function improved in four of seven patients, including libido and erection. This was paralleled by improved indices of wellbeing (physical fitness, mental alertness). In contrast, serum values of sexual hormones (testosterone or oestradiol) and of basal and stimulated (LHRH/TRH), prolactin and LH, and FSH were not significantly changed during rHuEpo therapy. © 1990 European Dialysis and Transplant Association-European Renal Association.

引用

页码：204 / 207

页数：4

共 17 条

[1]

BOMMER J, 1987, Nephrology Dialysis Transplantation, V2, P238

[2] CORRECTION OF THE ANEMIA OF END-STAGE RENAL-DISEASE WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN - RESULTS OF A COMBINED PHASE-I AND PHASE-II CLINICAL-TRIAL [J].